Ameritas Investment Partners’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.9K | Hold |
1,973
| – | – | ﹤0.01% | 2496 |
|
|
2025
Q4 | $31.1K | Hold |
1,973
| – | – | ﹤0.01% | 2413 |
|
|
2025
Q3 | $23.6K | Hold |
1,973
| – | – | ﹤0.01% | 2584 |
|
|
2025
Q2 | $14.9K | Hold |
1,973
| – | – | ﹤0.01% | 2799 |
|
|
2025
Q1 | $10.9K | Hold |
1,973
| – | – | ﹤0.01% | 2793 |
|
|
2024
Q4 | $11.3K | Hold |
1,973
| – | – | ﹤0.01% | 2870 |
|
|
2024
Q3 | $20.4K | Hold |
1,973
| – | – | ﹤0.01% | 2648 |
|
|
2024
Q2 | $25.6K | Hold |
1,973
| – | – | ﹤0.01% | 2509 |
|
|
2024
Q1 | $34.4K | Hold |
1,973
| – | – | ﹤0.01% | 2326 |
|
|
2023
Q4 | $18.6K | Hold |
1,973
| – | – | ﹤0.01% | 2610 |
|
|
2023
Q3 | $22K | Buy |
1,973
+496
| +34% | +$7.99K | ﹤0.01% | 2498 |
|
|
2023
Q2 | $31.6K | Hold |
1,477
| – | – | ﹤0.01% | 2303 |
|
|
2023
Q1 | $59.7K | Hold |
1,477
| – | – | ﹤0.01% | 1862 |
|
|
2022
Q4 | $73.2K | Hold |
1,477
| – | – | ﹤0.01% | 1805 |
|
|
2022
Q3 | $76K | Hold |
1,477
| – | – | ﹤0.01% | 1684 |
|
|
2022
Q2 | $69K | Hold |
1,477
| – | – | ﹤0.01% | 1764 |
|
|
2022
Q1 | $105K | Hold |
1,477
| – | – | ﹤0.01% | 1623 |
|
|
2021
Q4 | $110K | Hold |
1,477
| – | – | ﹤0.01% | 1619 |
|
|
2021
Q3 | $84K | Sell |
1,477
-181
| -11% | -$8.95K | ﹤0.01% | 1794 |
|
|
2021
Q2 | $73K | Hold |
1,658
| – | – | ﹤0.01% | 1925 |
|
|
2021
Q1 | $82K | Hold |
1,658
| – | – | ﹤0.01% | 1780 |
|
|
2020
Q4 | $70K | Hold |
1,658
| – | – | ﹤0.01% | 1777 |
|
|
2020
Q3 | $76K | Hold |
1,658
| – | – | ﹤0.01% | 1597 |
|
|
2020
Q2 | $83K | Buy |
1,658
+150
| +10% | +$7.76K | ﹤0.01% | 1526 |
|
|
2020
Q1 | $78K | Hold |
1,508
| – | – | ﹤0.01% | 1407 |
|
|
2019
Q4 | $93K | Buy |
1,508
+113
| +8% | +$7K | ﹤0.01% | 1555 |
|
|
2019
Q3 | $84K | Hold |
1,395
| – | – | ﹤0.01% | 1578 |
|
|
2019
Q2 | $118K | Hold |
1,395
| – | – | 0.01% | 1392 |
|
|
2019
Q1 | $133K | Hold |
1,395
| – | – | 0.01% | 1289 |
|
|
2018
Q4 | $99K | Hold |
1,395
| – | – | 0.01% | 1387 |
|
|
2018
Q3 | $119K | Buy |
1,395
+75
| +6% | +$7.51K | 0.01% | 1436 |
|
|
2018
Q2 | $153K | Buy |
1,320
+85
| +7% | +$8.48K | 0.01% | 1245 |
|
|
2018
Q1 | $100K | Hold |
1,235
| – | – | ﹤0.01% | 1492 |
|
|
2017
Q4 | $72K | Hold |
1,235
| – | – | ﹤0.01% | 1700 |
|
|
2017
Q3 | $52K | Hold |
1,235
| – | – | ﹤0.01% | 1875 |
|
|
2017
Q2 | $44K | Hold |
1,235
| – | – | ﹤0.01% | 1989 |
|
|
2017
Q1 | $38K | Buy |
+1,235
| New | +$38.5K | ﹤0.01% | 2012 |
|
Other funds holding ENTA
FCM
KAM
DTC
VCM
VPM
SSC
Ameritas Investment Partners's ENTA Position: Q1 2026 in Review
Ameritas Investment Partners held its Enanta Pharmaceuticals (ENTA) position steady in Q1 2026 at 1,973 shares worth $24.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2496.
Ameritas Investment Partners first reported a position in ENTA in Q1 2017 and has held it in 37 quarters since. The position peaked at $153K in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- Ameritas Investment Partners held 1,973 shares of Enanta Pharmaceuticals worth $24.9K as of Q1 2026.
- Ameritas Investment Partners left its Enanta Pharmaceuticals share count unchanged in Q1 2026.
- Enanta Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2496 holding.
- Ameritas Investment Partners first reported a position in Enanta Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
- Ameritas Investment Partners's Enanta Pharmaceuticals position peaked at $153K in Q2 2018.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.